Komori
Tms (4891) · InitiativeRestated

TMS-009's Role as a Backup

First written in FY2023-Q3. 2 of 6 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2025.

6entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023-Q3AdvancedFY2024-Q1 – FY2024-Q2RestatedFY2024-Q3 – FY20252023: 420232024: 120242025: 12025
Same theme, other companies
Positioning TMS-009 as a Backup and Development Candidate for TMS-008A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「The Company is preparing to develop TMS-009 as a backup compound for TMS-008. TMS-009 has properties similar to TMS-008, but showed greater pharmacological effects than TMS-008 in some animal studies. Accordingly, the Company is considering developing TMS-009 as the lead compound for certain indications rather than solely as a backup compound.」

    TMS-009 remains a backup for TMS-008, while development as the lead compound for certain indications remains under consideration.
  2. FY2024-Q3RestatedAnnual report

    「The Company is continuing to examine a specific manufacturing method for TMS-009, which is positioned as a backup for TMS-008.」

    The Company continues to examine a specific manufacturing method for TMS-009 while maintaining its backup positioning.
  3. FY2024-Q2AdvancedAnnual report

    「The Company has begun examining a specific manufacturing method for TMS-009, which is positioned as a backup for TMS-008.」

    TMS-009 remains a backup for TMS-008, while the Company has entered the stage of examining a specific manufacturing method.
  4. FY2024-Q1AdvancedAnnual report

    「The Company began preparations for exploratory manufacturing of TMS-009, which is positioned as a backup for TMS-008.」

    Preparations for exploratory manufacturing of TMS-009 began while it remained positioned as a backup for TMS-008.
  5. FY2023ReframedAnnual report

    「TMS-009 has properties similar to TMS-008, but showed greater pharmacological effects than TMS-008 in some animal studies. Accordingly, the Company is considering developing TMS-009 as the lead compound for certain indications rather than solely as a backup compound.」

    The Company indicated that TMS-009 could be developed as the lead compound for certain indications rather than remaining only a backup.
  6. FY2023-Q3First statedAnnual report

    「TMS-009 is positioned as a backup for TMS-008.」

    TMS-009 is positioned as a backup for TMS-008.
Moved together

"Preclinical development and preparation for Phase I clinical trials of TMS-008" moved the same way as this thread, in the same document, in 2 of its 6 moves.

222★123
  1. ★This thread
  2. 1Preclinical development and preparation for Phase I clinical trials of TMS-0082×
  3. 2Evaluation of External Assets for In-licensing2×
  4. 3Introduction of Academia-Based Drug Discovery Seeds and Bridging to Global Markets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tms yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
TMS-009's Role as a Backup | TMS Co.,Ltd. (4891) | Komori